Efficacy of digital cognitive behavioural therapy for insomnia in Armed Forces and Veteran populations - A systematic review and meta-analysis of randomised controlled trials.

Sleep MedApr 29, 2026 (epub)
Clinical ResearchPsychiatry

Alex J Rawcliffe, Sofia Isabel Ribeiro Pereira

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of digital cognitive behavioural therapy for insomnia (CBT-I) in Armed Forces personnel. Analyzing data from six randomized controlled trials involving 558 participants, the study found a statistically significant moderate-to-large reduction in insomnia severity, with a notable effect size. The overall risk of bias was assessed as moderate.

Key findings

  • Pooled post-treatment effects showed a moderate-to-large reduction in insomnia severity favoring digital CBT-I.
  • Three studies reported clinically meaningful reductions in Insomnia Severity Index scores of ≥6 points.
  • Follow-up assessments indicated maintenance of treatment gains up to 12 months.

Why it matters

Insomnia is prevalent in military populations and can significantly impact readiness and quality of life. Digital CBT-I offers a scalable solution to address this issue, particularly in settings where traditional therapy access is limited.

What to keep in mind

Overall risk of bias was unclear or high, primarily due to limited reporting and attrition.

Source

Published in Sleep Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.